Targeting Abdominal Obesity

Targeting Abdominal Obesity to Manage the Metabolic Syndrome

Page: 2 of 12

There is a wealth of evidence suggesting that intra-abdominal (visceral) adipose tissue, insulin resistance, and the development of the metabolic syndrome and/or type 2 diabetes are closely linked (1, 2). In addition to its ties to abdominal obesity, the metabolic syndrome has also been linked to blood lipid disorders, an inflammatory and pro-thrombotic state, hypertension, and insulin resistance. In this regard, Palaniappan et al. (3) found that the best predictors of incident metabolic syndrome over a 5 year follow-up were waist circumference, HDL cholesterol, and proinsulin levels. They examined a sample of 714 men aged 54.4 ± 8.5 years at the beginning of follow-up who participated in the Insulin Resistance Atherosclerosis (IRAS) Study. The authors suggested that steps should be taken to address components of the metabolic syndrome, such as waist circumference, in order to reduce the risk of developing the syndrome and related complications such as type 2 diabetes and cardiovascular disease. This study also showed that waist circumference was a better predictor of metabolic syndrome than directly measuring insulin sensitivity with an oral glucose tolerance test. The contribution of various lifestyle and therapeutic interventions to reducing body weight, abdominal fat in particular, and preventing insulin resistance and type 2 diabetes is examined below.

Reference

close

1. Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34: 1055-8.

2. Pascot A, Després JP, Lemieux I, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000; 43: 1126-35.

3. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 788-93.

Page: 2 of 12

Print this document